Evaluating CLL treatment efficacy
INVITATION
Evaluating CLL treatment efficacy: how to interpret progression-free survival, time to next treatment and MRD?
In recent years we have moved away from chemoimmunotherapy (CIT) toward the use of novel targeted agents, such as BTK and BCL2 inhibitors, which are now the mainstay of therapy both in the frontline and in relapsed settings.
In addition, detection of measurable residual disease (MRD) has emerged as a sensitive tool to assess disease burden following treatment, and is commonly included in most clinical trials, demonstrating prognostic value and capability to guide treatment duration, de-escalation and intensification of treatment to improve outcomes in terms of the balance between treatment efficacy and toxicity.
With this complete transformation of the treatment landscape for CLL, it could be essential to critically reassess traditional criteria for evaluating efficacy and safety. This could be especially important considering patients’ demand for a more inclusive endpoint: ‘the clinical benefit’.
The speakers will address these topics and discuss how they can be incorporated in the clinical setting.
Chairs: Prof. Per-Ola Andersson & Prof. Emerita Eva Kimby
Register
Date: November 17th, 2025
Place: Clarion Hotel Arlanda, Sweden, room Tokyo and via stream
Time: 17.15 -19.20, followed by light dinner for those participating live
Participate on site HERE
Participate online HERE
If you have any questions about the meeting, please contact Erik Bissessar, [email protected]
A warm welcome!
Lilly bekostar, i enlighet med LER, förtäring för deltagare på plats, lokalkostnad och föreläsararvode inom ramen för mötet.
Program
17.15 Welcome and introduction | Prof. Per-Ola Andersson
17.25 How we treat CLL patients today compared to in the past – a short walkthrough of how the guidelines have evolved | Prof. Emerita Eva Kimby
17.40 Minimal residual disease assessment in CLL – proxy for efficacy or guiding treatment? | Ass. Prof. Carsten Niemann
18.10 Redefining efficacy and safety endpoints for CLL in the era of targeted therapy | Prof. Stefano Molica
18.50 Panel discussion
19.20 Thank you and goodbye to online participants
19.30 Dinner
Eli Lilly Sweden AB | Box 721, 169 27 Solna 08-737 88 00 | www.lilly.com/se
PP-PT-SE-0054 Oktober 2025
